CD19 positive

P1, N=35, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Nov 2025 | Trial primary completion date: Jun 2026 --> Nov 2025

P1, N=12, Completed, National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting --> Completed | N=18 --> 12

This novel assay met GMP/GLP compliance, allowing a quantifiable and reproducible measure of efficacy, ensuring batch-to-batch consistency, and met safety and effectiveness regulatory requirements. This potency assay may be applicable for testing other CD3-CD19 T cell engagers and suitable for developing other diabody mediated potency assays with appropriate antigens.

P=N/A, N=150, Recruiting, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; Longhua Hospital Affiliated to Shanghai University of Traditional

P=N/A, N=19, Not yet recruiting, The First Affiliated Hospital of the University of Science and Technology of China; The First Affiliated Hospital of the University of Science and Tec

P=N/A, N=8, Not yet recruiting, Nanfang Hospital Ganzhou Hospital (Ganzhou People's Hospital); Ganzhou People's Hospital

P1/2, N=17, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Aug 2040 --> Sep 2037 | Trial primary completion date: Dec 2025 --> Sep 2025

P1/2, N=17, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=54 --> 17 | Trial completion date: Apr 2041 --> Aug 2040 | Trial primary completion date: Apr 2026 --> Dec 2025

We report a case of a 29-year-old woman with refractory stage IV-B THRLBCL treated with anti-CD19 CAR T-cell therapy (varnimcabtagene autoleucel), who achieved an initial response (day +28) but experienced disease progression by day +100 despite robust CAR T-cell expansion. The patient remains in sustained remission, with persistent B-cell aplasia, four years post-intervention. This case provides clinical and pathological evidence supporting the use of immune checkpoint blockade to rescue CAR T-cell efficacy, highlighting the potential of this synergistic approach in THRLBCL and possibly other B-cell malignancies exhibiting similar immune evasion.

P1, N=37, Active, not recruiting, City of Hope Medical Center | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026

P1, N=140, Recruiting, Iksuda Therapeutics Ltd. | Trial completion date: Sep 2027 --> Sep 2028 | Trial primary completion date: Sep 2025 --> Sep 2026

This case underscores the clinical importance of recognizing atypical HUV presentations without urticaria and highlights the association of hypocomplementemia and thrombocytopenia with underlying hematologic malignancy. In patients with autoimmune background and cutaneous vasculitic lesions, hematologic malignancies should be considered, and thorough evaluation is essential to exclude paraneoplastic processes.